In particular, obesity-specific endocrine alterations significantly contribute to the impairment in GH activity: decreased adiponectin levels, an adipokine that exerts anti-inflammatory and anti-fibrotic effect, and increased somatostatin, are the main drivers of GH deficient action. This evidence concerns the gene GH1 and obesity disorder.